Halozyme Therapeutics Hits New 52-Week High of $79.31, Up 53% Yearly

Halozyme Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 79.31 on September 22, 2025. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, where it has demonstrated a remarkable one-year performance of 53.01%, significantly outpacing the S&P 500's 16.64% return.
With a market capitalization of USD 8,872 million, Halozyme is classified as a small-cap company. The stock exhibits a price-to-earnings (P/E) ratio of 14.00, indicating a favorable valuation relative to its earnings. The company has shown impressive management efficiency, highlighted by a return on equity (ROE) of 167.48% and a robust operating profit growth rate of 73.99% annually.

Additionally, Halozyme's financial health is reflected in its strong EBIT to interest ratio of 23.90, showcasing its ability to manage debt effectively. The stock's performance has been bolstered by consistent positive results over the last six quarters, with a notable net profit growth of 39.85%. As the company continues to thrive, its recent high marks a pivotal moment in its ongoing journey.